
Source briefing
Russia Punishes Independent Researcher for Being Cited
Click to expand Image Olga Sibireva. © Private Those reporting on Russia are rarely surprised these days to learn that another critic of the Russian government is being prosecuted over alleged involvement with a “foreign undesirable organization.” But…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Withdrawn
Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Withdrawn
Read →
Source briefing
Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised
Read →
Source briefing
Communicable disease threats report, 5 -11 September, week 37
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5 -12 September, and includes updates on Ebola, an overview of respiratory virus epidemiology in the EU/EEA, West Nile virus, Crimean-Congo haemorrhagic fever, dengue, chikungunya,…
Read →
Source briefing
Country- and individual-level factors associated with healthy working life expectancy: A multinational longitudinal study
by Jingjie Zhu, Bo Ye, Zeyu Huang, Huazhen You, Junjia Jiang, Shitong Yang, Junling Gao Background To address labor force shortages associated with population aging, many countries have proposed raising the retirement age. As health is an important…
Read →
Source briefing
Where U.S. has lost ground since 9/11
FDNY chief, admiral who survived Pentagon attack, Time journalist say decline in national unity since then is perhaps most damaging problem
Read →
Source briefing
Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 38, Status: Authorised
Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 38, Status: Authorised
Read →
Source briefing
HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026
HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026
Read →
Source briefing
Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 25, Status: Authorised
Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 25, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised
Read →